Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization

Fujiyama, Toshiharu; Oze, Isao; Yanagimoto, Hiroaki; Hashizume, Hideo; Matsuo, Keitaro; Hino, Ryosuke; Kamo, Riei; Imayama, Shuhei; Hirakawa, Satoshi; Ito, Taisuke; Takigawa, Masaharu; Tokura, Y.

doi:10.1016/j.jdermsci.2014.04.005

Cited by 15 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1A. The frequencies of the CTLs in the 6 patients were significantly higher than those of controls that were evaluated previously [6] (Fig. 1B).…”

mentioning

confidence: 58%

“…HLA-A genotyping was performed in all patients. The frequency of Melan-A-specific CTLs was assessed by tetramer in patients with HLA-A of A*02:01:01, and tyrosinase-specific CTLs was assessed by pentamer in those with A*24:02 [6]. The specific peptides for Melan-A for HLA-A*02:01:01 and tyrosinase for HLA-A*24:02 are ELAGIGLTV and AFLPWHRLF, respectively.…”

mentioning

confidence: 99%

“…The specific peptides for Melan-A for HLA-A*02:01:01 and tyrosinase for HLA-A*24:02 are ELAGIGLTV and AFLPWHRLF, respectively. Previously, we reported the frequency of the Melan-A and tyrosinase specific CTLs in six healthy controls bearing matched HLA-A, and when the CTLs frequency was greater than mean + 2SD of the control, we considered the value as positive for the CTLs [6]. Anti-nuclear antibody (ANA), anti-thyroid autoantibodies (anti-thyroglobulin and anti-thyroperoxidase antibodies), and thyroid function were screened.…”

mentioning

confidence: 99%

“…Our previous investigation for the vaccination and induction of the CTLs in advanced melanoma patients suggested that Melan-Aspecific CTLs could be more easily and successfully induced than the tyrosinase-specific CTLs [6]. The frequency of Melan-A-specific CTLs was significantly higher in melanoma patients than in healthy donors even before the vaccination, while the frequency of tyrosinase-specific CTLs was not significantly elevated before vaccination [6]. Among the 6 cases of HLA-A*02:01:01, there was a tendency that the frequency of CTLs correlated with the % BSA (P = 0.064, Fig.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma

Fujiyama

Ikeya

Ito

et al. 2015

Journal of Dermatological Science

Self Cite

View full text Add to dashboard Cite

“…1A. The frequencies of the CTLs in the 6 patients were significantly higher than those of controls that were evaluated previously [6] (Fig. 1B).…”

mentioning

confidence: 58%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma

Fujiyama

Ikeya

Ito

et al. 2015

Journal of Dermatological Science

Self Cite

View full text Add to dashboard Cite

“…Besides, patients with longer survival were those in whom peptide-specific immunity has been induced to at least two melanoma peptides [113]. Other studies have shown that the induction of CTLs is an independent survival factor in malignant melanoma patients treated with percutaneous peptide immunization [114] as well as patients treated with a DC vaccine [115]. In the latter study, cessation of CTL responses in melanoma patients has been shown to be associated with disease progression [115].…”

Section: Applications In Clinical Trialsmentioning

confidence: 95%

MAGE-A3: an Immunogenic Target Used in Clinical Practice

Esfandiary

Ghafouri‐Fard

2015

Immunotherapy

View full text Add to dashboard Cite

Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As antigen-specific immune responses can be stimulated by immunization with MAGE-A3, several clinical trials have used MAGE-A3 vaccines to observe clinical responses. The frequent expressions of this antigen in various tumors and its immunogenicity in cancer patients have led to application of this antigen in cancer immunotherapy. However, the results of recent clinical trials indicate that there is a need for research in the vaccine design, adjuvant selection as well as patient selection criteria.

show abstract

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Kitaoka

Wakabayashi

Kamiya

et al. 2016

Biotechnology Journal

View full text Add to dashboard Cite

Transdermal administration of drugs has advantages over conventional oral administration or administration using injection equipment. The route of administration reduces the opportunity for drug evacuation before systemic circulation, and enables long‐lasting drug administration at a modest body concentration. In addition, the skin is an attractive route for vaccination, because there are many immune cells in the skin. Recently, solid‐in‐oil nanodisperison (S/O) technique has demonstrated to deliver cosmetic and pharmaceutical bioactives efficiently through the skin. S/O nanodispersions are nanosized drug carriers designed to overcome the skin barrier. This review discusses the rationale for preparation of efficient and stable S/O nanodispersions, as well as application examples in cosmetic and pharmaceutical materials including vaccines. Drug administration using a patch is user‐friendly, and may improve patient compliance. The technique is a potent transcutaneous immunization method without needles.

show abstract

Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization

Cited by 15 publications

References 33 publications

Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma

Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma

MAGE-A3: an Immunogenic Target Used in Clinical Practice

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Contact Info

Product

Resources

About